Table 3.
Impact of PCLX-001 treatment on the intracellular level of HGAL, Lyn, NMT1, and NMT2 in CD4+ T cells, CD8+ T cells, CD19+ B cells, and CD14+ monocytes.
| Cell Populations | Screening Sample (%) | Day 1 (%) | Day 28 (%) |
|---|---|---|---|
| CD4+ T cells | |||
| HGAL | 12.7 ± 0.57 | 22.1 ± 0.73 | 8.6 ± 0.58 |
| Lyn | 13.7 ± 0.28 | 20 ± 0.28 | 28.7 ± 0.37 |
| NMT1 | 2.99 ± 0.69 | 4.87 ± 0.63 | 2.22 ± 0.63 |
| NMT2 | 22.8 ± 0.33 | 25.7 ± 0.31 | 35.3 ± 0.36 |
| CD8+ T cells | |||
| HGAL | 25 ± 0.61 | 30.3 ± 0.58 | 17 ± 0.63 |
| Lyn | 17.6 ± 0.17 | 25.8 ± 0.28 | 33.3 ± 0.31 |
| NMT1 | 0.94 ± 0.55 | 0.85 ± 0.64 | 0.77 ± 0.38 |
| NMT2 | 11 ± 0.11 | 12.7 ± 0.27 | 18.7 ± 0.33 |
| CD19+ B cells | |||
| HGAL | 2.44 ± 0.41 | 11.2 ± 0.51 | 8.33 ± 0.39 |
| Lyn | 8.33 ± 0.29 | 12.4 ± 0.27 | 12.1 ± 0.15 |
| NMT1 | 0.98 ± 0.41 | 2.65 ± 0.71 | 2.42 ± 0.42 |
| NMT2 | 31.8 ± 0.29 | 29 ± 0.3 | 33.3 ± 0.24 |
| CD14+ Monocytes | |||
| HGAL | 83.9 ± 0.64 | 87.5 ± 0.65 | 88.3 ± 0.64 |
| Lyn | 51.4 ± 0.50 | 40.5 ± 0.39 | 66.6 ± 0.59 |
| NMT1 | 1.59 ± 0.19 | 1.37 ± 0.33 | 4.55 ± 0.30 |
| NMT2 | 6.21 ± 0.45 | 6.7 ± 1.13 | 11.7 ± 0.17 |
PBMC were isolated from patient 1 after 28 days of treatment with PCLX-001 and analysed by flow cytometry. Intracellular staining allowed us to analyse HGAL, NMT1 (A), Lyn, and NMT2 levels in CD4+ T cells, CD8+ T cells (A), B cells (CD19+), and monocytes (CD14+) population. Values are expressed as % of population ± CV.